95 related articles for article (PubMed ID: 10344729)
1. Decay accelerating factor (CD55): a target for cancer vaccines?
Spendlove I; Li L; Carmichael J; Durrant LG
Cancer Res; 1999 May; 59(10):2282-6. PubMed ID: 10344729
[TBL] [Abstract][Full Text] [Related]
2. Immunization against tumor cell surface complement-regulatory proteins.
Durrant LG; Spendlove I
Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
[TBL] [Abstract][Full Text] [Related]
3. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
[TBL] [Abstract][Full Text] [Related]
4. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Kallmeyer C; Pritchard-Jones K; Durrant LG
Clin Immunol; 2008 Aug; 128(2):148-54. PubMed ID: 18508409
[TBL] [Abstract][Full Text] [Related]
5. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
[TBL] [Abstract][Full Text] [Related]
6. CD55 is over-expressed in the tumour environment.
Li L; Spendlove I; Morgan J; Durrant LG
Br J Cancer; 2001 Jan; 84(1):80-6. PubMed ID: 11139317
[TBL] [Abstract][Full Text] [Related]
7. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
Chen S; Caragine T; Cheung NK; Tomlinson S
Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor.
Osuka F; Endo Y; Higuchi M; Suzuki H; Shio Y; Fujiu K; Kanno R; Oishi A; Terashima M; Fujita T; Gotoh M
Genomics; 2006 Sep; 88(3):316-22. PubMed ID: 16503113
[TBL] [Abstract][Full Text] [Related]
9. Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex.
Heine H; Ulmer AJ; El-Samalouti VT; Lentschat A; Hamann L
J Endotoxin Res; 2001; 7(3):227-31. PubMed ID: 11581575
[TBL] [Abstract][Full Text] [Related]
10. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2.
Zeytin HE; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; Chatterjee SK
Cancer Gene Ther; 2000 Nov; 7(11):1426-36. PubMed ID: 11129285
[TBL] [Abstract][Full Text] [Related]
12. CD55/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex.
Heine H; El-Samalouti VT; Nötzel C; Pfeiffer A; Lentschat A; Kusumoto S; Schmitz G; Hamann L; Ulmer AJ
Eur J Immunol; 2003 May; 33(5):1399-408. PubMed ID: 12731067
[TBL] [Abstract][Full Text] [Related]
13. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
15. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
16. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers.
Coggin JH; Barsoum AL; Rohrer JW
Anticancer Res; 1999; 19(6C):5535-42. PubMed ID: 10697612
[TBL] [Abstract][Full Text] [Related]
17. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
18. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
19. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions.
Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P
Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor.
Okada N; Tanaka H; Takizawa H; Okada H
J Immunol; 1995 Jun; 154(11):6103-11. PubMed ID: 7538542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]